Scholars Central

OtherPublished 13 Jul 2016

Pridopidine in the pharmacological treatment of Huntingtons disease

Authors: Martin Michl, Katharina Schnopfhagen, Raphael M Bonelli

Clinical Investigation

Volume 3 · Issue 7 · Pages 691

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The available treatment options for Huntington’s disease (HD) are only symptomatic, partly with a limited symptom control and often accompanied by serious side effects. This review summarizes the current management of HD and elucidates why pridopidine might represent a turning point in the treatment of the condition. Pharmacology, clinical evidence, safety and tolerability of the drug will also be addressed. As pridopidine is a member of a new class of compounds, it opens up the field for new treatment strategies that might be more efficient in controlling motor symptoms, with fewer side effects than the treatment options currently available. In a Phase II and III study, pridopidine significantly improved motor functions in Huntington patients with an adverse-event profile comparable to that of a placebo.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Martin Michl”
  • BylineArticles whose byline prints “Katharina Schnopfhagen”
  • BylineArticles whose byline prints “Raphael M Bonelli”